Could optogenetics represent the innovative thinking needed to restore some function in retinitis pigmentosa (RP) patients? Allen Ho, MD, joins us to discuss the state of play in optogenetics, specifically regarding MCO-010 (Nanoscope Therapeutics). What have we seen in the several years since the first patients with RP were dosed with MCO-010 in the RESTORE study? And Charles Wykoff, MD, PhD, joins us to review data assessing the safety and efficacy of sura-vec (Regenxbio/AbbVie) for the treatment of non-proliferative diabetic retinopathy. What do patients look like at 2 years after a single suprachoroidal injection? Listen in to find out.